Open Access

Low expression of microRNA-204 (miR-204) is associated with poor clinical outcome of acute myeloid leukemia (AML) patients

  • Aleksandra Butrym1, 2Email author,
  • Justyna Rybka1,
  • Dagmara Baczyńska3,
  • Andrzej Tukiendorf4,
  • Kazimierz Kuliczkowski1 and
  • Grzegorz Mazur5
Journal of Experimental & Clinical Cancer Research201534:68

https://doi.org/10.1186/s13046-015-0184-z

Received: 1 April 2015

Accepted: 24 June 2015

Published: 1 July 2015

Abstract

Background

Acute myeloid leukemia (AML) is a heterogeneous neoplasm of the bone marrow with poor prognosis. In clinical practice new prognostic factors are still needed. MicroRNAs (miRs), small endogenous noncoding RNAs, play an essential role in the development and progression of acute leukemia. The aim of the study was to evaluate miR-204 expression in patients with AML at diagnosis and after induction chemotherapy, in comparison to healthy controls. We also investigated, if miR-204 expression correlates with clinical features of AML patients.

Methods

miR-204 expression has been analyzed using RT-PCR in 95 bone marrow specimens from newly diagnosed AML patients in comparison to 20 healthy subject.

Results

We showed down-regulated miR-204 expression in AML patients, which was associated with shorter patients’ survival. Higher expression of miR-204 in patients after induction therapy was correlated with complete remission achieving.

Conclusions

We showed low miR-204 expression in AML and found it to be an independent prognostic factor in this patient population.

Keywords

miR-204Acute myeloid leukemiaExpressionSurvivalPrognosis

Introduction

Acute myeloid leukemia (AML) in adults is a hematological malignancy with proliferation of myeloblasts in the bone marrow. Population of AML patients has heterogenous clinical course and different prognosis. Although dynamic progress on the field of pathogenesis and development of this blood cancer has been made, it is still difficult to predict clinical outcome and response to therapy of AML patients. Genetic and molecular markers are used in every day practice, but new predictors are needed, for better patients’ classification and therapy planning [1, 2].

microRNA (miRs) are small non-coding RNAs, which play an important role in neoplastic transformation. miRs act by influencing posttranscriptional gene expression, cell development, differentiation, proliferation and apoptosis [38].

microRNA-204 (miR-204) role has been investigated and described in few solid tumors, particularly pancreatic and colorectal cancer, where it was found to be associated with process of autophagy [3, 9]. But there is no data about miR-204 role in acute myeloid leukemia. The purpose of this study was to evaluate miR-204 expression in AML patients in relation to clinical factors, survival and comparison to healthy subjects.

Material and methods

Patients characteristic

The study included 95 patients (aged 60.2 ± 15.0, 22–90, Male = 61 %) with newly diagnosed AML. Samples of the bone marrow for miR-204 expression analysis were collected before start of chemotherapy and repeated after completed induction chemotherapy (in 40 patients). Patients were treated in the Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation of Wroclaw Medical University, Wroclaw, Poland. A control group of 20 healthy subjects was also taken into account (aged 64.2 ± 10.5, 39–80, Male = 65 %). According to AML FAB classification, 7 patients had AML M0, 34 had M1, 29 had M2, 14 had M4 and 11 had M5. There were 73 patients with primary leukemia and 22 patients with leukemia secondary to myelodysplastic or myeloproliferative syndrome. Summary of patients’ characteristics is presented in Table 1.
Table 1

Clinical characteristics of patients with AML

Characteristic

Cases

Sex

 

   Male

56

   Female

39

Age (years)

 

   Range

22-90

   Median

61

FAB subtype

 

   M0

7

   M1/M2

63

   M4/M5

25

WBC (G/L)

 

   Range

0.2-295

   Median

14

HGB g%

 

   Range

5.8-13.1

   Median

9.3

PLT (G/L)

 

   Range

2-310

   Median

65

Lactate dehydrogenase (LDH) U/l

 

   Range

108-4565

   Median

340

Blasts in bone marrow

 

   <50 %

35

   ≥50 %

60

Cytogenetics

 

   Farorable

5

   Intermediate

39

   Unfavorable

51

Chemotherapy

 

   Intensive

56

   Low dose

27

   Best supportive care

12

Molecular tests

Total 60 patients

   AML/ETO (positive/negative)

4/56

   CBFb-MYH11 (positive/negative)

2/58

   NPM1 (positive/negative)

7/53

   FLT3/ITD (positive/negative)

13/47

Complete remission

 

   Yes (total)

51

      Yes (after 1st line therapy)

36

   No

44

Duration of remission (months)

 

   Range

2-54

   Median

20

Time to relapse (months)

 

   Range

3-23

   Median

12

Survival (months)

 

   Range

0-55

   Median

3

Treatment schedules

Fifty six patients were treated with standard induction intensive chemotherapy (daunorubicin plus cytarabine 3 + 7), 27 received low dose chemotherapy (low dose cytarabine or azacitidine) and 12 best supportive care only. After completion of induction therapy response to treatment was evaluated. CR was defined by Cheson criteria. [10]. 40 bone marrow samples were re-evaluated for miR-204 expression after chemotherapy. Patients were followed up for median 21 month (range 1–40 months).

Research was carried out in compliance with the Helsinki Declaration. For the study approval of Bioethical Committee of Wroclaw Medical University was obtained. Written informed consent for study was obtained from all the participants.

Isolation and expression analysis of microRNAs

Bone marrow mononuclear cells (PBMC) were isolated by Ficoll-Hypaque density gradient centrifugation. Total RNA and microRNA were extracted from collected AML mononuclear cells using mirVana™ miRNA Isolation Kit (Ambion) according to the protocol of the manufacturer. Then 5 μl total miRNA was used as a template into synthesis of cDNA using TaqMan MicroRNA Trasncription Reaction Kit (Applied Biosystems) and 3 μl specific miRNA primers from the TaqMan MicroRNA Assays (Applied Biosystems). Individual reaction was carried out in 15 μl total volume in thermal condition: 16 °C for 30 min, 42° for 30 min, 85 °C for 5 min. TaqMan MicroRNA Assays for miR-204 (hsa-miR-204), and RNU48 were used. The expression level of each microRNA was measured in relative real-time PCR method using TaqMan Gene Expression Assays and TaqMan Fast Universal PCR Master Mix (Applied Biosytems). All reactions were done in triplicate in a total volume of 20 μl on 96-well plates. The real-time PCR was performed on 7900HT Fast Real-Time PCR System (Applied Biosystems) under thermal cycling conditions: 20 s at 95 °C and 40 cycles of 1 s at 95 °C and 20 s at 60 °C. For quantification, the samples were normalized against the expression of RNU48 (internal control). Relative quantification factors (RQ) for the examined miRs were calculated using ΔΔCT method.

Statistical analysis

The differences in means of gene expressions between the study and the control patients were estimated using t-Student’s test (for independent samples). To examine the time it takes for death and remission to occur, a Cox’s regression was applied [11]. The difference between the gene expressions before and after treatment was estimated using robust regression and multivariate approach [12]. The computation was performed in R software [13] and based on the simulation technique known as Gibbs sampling in WinBUGS platform [14]. Kaplan-Meier survival curves were used to determine any significant relationship between miR-204 expression and clinical outcome. Results were considered statistically significant when p was <0.05.

Results

We compared AML samples to healthy controls and found significantly lower miR-204 expression in AML patients (p < 0.05). There were no differences in miR-204 expression between male and female patients.

After successful induction chemotherapy expression of miR-204 significantly increased (median 0.443606; p = 0.000590). Patients with increased miR-204 expression after induction therapy had higher chance for remission (p = 0.01438). 83 % of pts with CR after induction therapy had high miR-204 expression and 60 % of patients who did not respond to therapy had low miR-204 expression (Fig. 1). At the moment of diagnosis, Mean miR-204 expression in group who achieved CR was significantly lower than in the group which did not achieve response.
Fig. 1

Correlation between miR-204 expression after chemotherapy and remission

In patients with increase of miR-204 expression after chemotherapy time to relapse was longer (median 13 months) than in patients with decreased miR-204 expression (median 4.5 months), p = 0.003347, Fig. 2.
Fig. 2

miR-204 expression after chemotherapy and time to relapse

miR-204 expression level also influenced patients’ outcome (median value was used as a cut-off). Higher miR-204 expression before therapy was associated with longer survival (Fig. 3).
Fig. 3

Predicted overall survival depending on miR-204 expression before chemotherapy

Discussion

Small non-coding microRNAs affect process of formation, development, proliferation and apoptosis of normal and malignant cells in human body. Their role has been proved in many cancers, including leukemia [4, 1517]. Pathways regulation based on microRNA expression is still unknown. Some miRs may act as tumor suppressors and others as oncogenes [18, 19]. Recently, many miRs have been investigated as prognostic and predictive markers. miR-204 expression and its role has been studied in some solid tumors: pancreatic, gastric, prostate [3, 9, 20], in which it acts by down-regulation of Bcl-2 and has tumor suppressor role. miR-204 also influences NTRK2 gene expression in neuroblastoma cancer [21] and FOXC1 gene in invasive endometrial cancer [22].

In our study we showed down-regulated expression of miR-204 in acute myeloid leukemia patients comparing to healthy controls which is in line with observation made by Garzon et al. [23]. Authors found lower miR-204 expression in nucleophosmin positive AML patients and assumed hypothesis, that miR-204 targeted HOXA10 and MEIS1. Those two genes perturb myeloid differentiation and can lead to AML. Ying et al. in their study revealed that loss of miR-204 promotes cancer cell migration through increased expression of brain derived neurotrophic factor or its TrkB receptor [24]. In gastric cancer loss of miR-204 expression was associated with poor outcome, because it caused increase of antiapoptotic protein Bcl-2. In the light of these results Chen et al. demonstrated that miR-204 was down-regulated and its overexpression leaded to loss of cancer cell viability in pancreatic cancer [3]. Authors also showed that miR-204 regulates expression of Mcl-1 (Myeloid cell leukemia) by direct binding to 3′UTR [3]. Overexpressed Mcl-1 is associated with cell survival, while its downregulation leads to cell death. Increased miR-204 negatively regulated Mcl-1. Those observations could explain results of our study. We also analyzed correlations between miR-204 at diagnosis and after chemotherapy and clinical outcome. After effective induction chemotherapy we observed increased miR-204 expression and this change correlated positively with chance for remission achieving. Supposedly higher miR-204 expression could induce leukemic cell deaths and leaded to disease remission. On the other side, patients who had higher miR-204 expression at diagnosis had more favorable clinical outcome than others. Similar role of miR-204 has been also proved in gliomas, where low miR-204 expression leaded to a stem cell-like phenotype, and its overexpression resulted in reduced tumorigenicity and loss of stemness transcription factor SOX4 [24]. In contrast were results by Sümbül et al., who detected high miR-204 expression in colorectal cancer in comparison to healthy population. This finding was not related to any clinicopathological parameters nor survival [9]. Authors explained discrepant findings by the role of increased miR-204 in autophagy and apoptosis.

Concluding, as to our knowledge, we found for the first time down-regulated miR-204 expression in acute myeloid leukemia patients with its implication to disease prognosis. Functionality of miR-204 acting as a tumor suppressor makes this new molecule an useful biomarker in cancer diagnosis and management. Further investigation on miR-204 regulation and its target genes should be performed.

Declarations

Acknowledgments

The study was supported by Wroclaw Medical University Grant number ST-486.

Authors’ Affiliations

(1)
Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University
(2)
Department of Physiology, Wroclaw Medical University
(3)
Department of Forensic Medicine, Molecular Techniques Unit, Wroclaw Medical University
(4)
Department of Epidemiology, Cancer Center-Institute of Oncology
(5)
Department of Internal and Occupational Diseases and Hypertension, Wroclaw Medical University

References

  1. Ustun C, Marcucci G. Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia. Curr Opin Hematol. 2015;22:85–91.PubMedView ArticleGoogle Scholar
  2. Estey EH. Acute myeloid leukemia: 2014 update on risk-stratification and management. Am J Hematol. 2014;89:1063–81.PubMedView ArticleGoogle Scholar
  3. Chen Z, Sangwan V, Banerjee S, Mackenzie T, Dudeja V, Li X, Wang H et al. miR-204 mediated loss of Myeloid cell leukemia-1 results in pancreatic cancer cell death. Mol Cancer. 2013;12:105. doi:10.1371/journal.pone.0052397.
  4. Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, et al. Reprogramming of miRNA networks in cancer and leukemia. Genome Res. 2010;20:589–99.PubMed CentralPubMedView ArticleGoogle Scholar
  5. Imam JS, Plyler JR, Bansal H, Prajapati S, Bansal S, Rebeles J, et al. Genomic loss of tumor suppressor miRNA-204 promotes cancer cell migration and invasion by activating AKT/mTOR/Rac1 signaling and actin reorganization. PLoS One. 2012;7(12), e52397. doi:10.1371/journal.pone.0052397.PubMed CentralPubMedView ArticleGoogle Scholar
  6. Liu J, Xue H, Zhang J, Suo T, Xiang Y, Zhang W, et al. MicroRNA-144 inhibits the metastasis of gastric cancer by targeting MET expression. J Exp Clin Cancer Res. 2015;34:35.PubMed CentralPubMedView ArticleGoogle Scholar
  7. Yu G, Yao W, Xiao W, Xu H, Li H, Lang B. MicroRNA-34a functions as an anti-metastatic microRNA and suppresses angiogenesis in bladder cancer by directly targeting CD44. J Exp Clin Cancer Res. 2014;33:779.PubMed CentralPubMedView ArticleGoogle Scholar
  8. Wang C, Zheng X, Shen C, Shi Y. MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. J Exp Clin Cancer Res. 2012;31:58.PubMed CentralPubMedView ArticleGoogle Scholar
  9. Sümbül AT, Göğebakan B, Ergün S, Yengil E, Batmacı CY, Tonyalı Ö, et al. miR-204-5p expression in colorectal cancer: an autophagy-associated gene. Tumour Biol. 2014;35:12713–9.PubMedView ArticleGoogle Scholar
  10. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al. International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642–9.PubMedView ArticleGoogle Scholar
  11. Cox DR. Regression models and life-tables. J Royal Stat Soc B. 1972;34:187–220.Google Scholar
  12. Congdon P. Applied Bayesian modelling. Chichester: Wiley; 2003. p. 118–26.View ArticleGoogle Scholar
  13. R Core Team. R: A language and environment for statistical computing. Version 3.0.3. 2014 Vienna: R Foundation for Statistical Computing, http://www.r-project.org/]
  14. Spiegelhalter D, Thomas A, Best N, Lunn D. WinBUGS. Version 1.4.3. 2003. Cambridge: Imperial College School of Medicine & Medical Research Council-Biostatistics Unit, www.mrc-bsu.cam.ac.uk/bugs/winbugs/).
  15. Weng H, Lal K, Yang FF, Chen J. The pathological role and prognostic impact of miR-181 in acute myeloid leukemia. Cancer Genet. 2015;S2210-7762(14):00288–9. doi:10.1016/j.cancergen.2014.12.006.
  16. Butrym A, Rybka J, Baczyńska D, Tukiendorf A, Kuliczkowski K, Mazur G. Expression of microRNA-331 can be used as a predictor for response to therapy and survival in acute myeloid leukemia patients. Biomark Med. 2015;26:1–8.Google Scholar
  17. Li W, Jin X, Zhang Q, Zhang G, Deng X, Ma L. Decreased expression of miR-204 is associated with poor prognosis in patients with breast cancer. Int J Clin Exp Pathol. 2014;7:3287–92.PubMed CentralPubMedGoogle Scholar
  18. Xia Y, Zhu Y, Ma T, Pan C, Wang J, He Z, et al. miR-204 functions as a tumor suppressor by regulating SIX1 in NSCLC. FEBS Lett. 2014;588:3703–12. doi:10.1016/j.febslet.2014.08.016.PubMedView ArticleGoogle Scholar
  19. Wang T, Li F, Tang S. MiR-30a upregulates BCL2A1, IER3 and cyclin D2 expression by targeting FOXL2. Oncol Lett. 2015;9:967–71.PubMed CentralPubMedGoogle Scholar
  20. Todorova K, Metodiev MV, Metodieva G, Zasheva D, Mincheff M, Hayrabedyan S. miR-204 is Dysregulated in Metastatic Prostate Cancer In Vitro. Mol Carcinog. 2015; doi:10.1002/mc.22263
  21. Ryan J, Tivnan A, Fay J, Bryan K, Meehan M, Creevey L, et al. MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome. Br J Cancer. 2012;107:967–76.PubMed CentralPubMedView ArticleGoogle Scholar
  22. Chung TK, Lau TS, Cheung TH, Yim SF, Lo KW, Siu NS, et al. Dysregulation of microRNA-204 mediates migration and invasion of endometrial cancer by regulating FOXC1. Int J Cancer. 2012;130:1036–345.PubMedView ArticleGoogle Scholar
  23. Garzon R, Garofalo M, Martelli MP, Briesewitz R, Wang L, Fernandez-Cymering C, et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc natl Acad Sci USA. 2008;105:3945–50.PubMed CentralPubMedView ArticleGoogle Scholar
  24. Ying Z, Li Y, Wu J, Zhu X, Yang Y, Tian H, et al. Loss of miR-204 expression enhances glioma migration and stem cell-like phenotype. Cancer Res. 2013;12:990–9.View ArticleGoogle Scholar

Copyright

© Butrym et al. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement